Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells In vitro and In vivo

@article{Hofstetter2005PatupiloneAA,
  title={Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells In vitro and In vivo},
  author={Barbara Hofstetter and Van Vuong and Angela Broggini‐Tenzer and Stephan Bodis and I. Frank Ciernik and Doriano Fabbro and Markus Wartmann and Gerd Folkers and Martin Pruschy},
  journal={Clinical Cancer Research},
  year={2005},
  volume={11},
  pages={1588 - 1596}
}
Interference with microtubule function is a promising antitumoral concept. Paclitaxel is a clinically validated tubulin-targeting agent; however, treatment with paclitaxel is often limited by taxane-related toxicities and is ineffective in tumors with multidrug-resistant cells. Patupilone (EPO906, epothilone B) is a novel non-taxane-related microtubule-stabilizing natural compound that retains full activity in multidrug-resistant tumors and is clinically less toxic than paclitaxel. Here we have… 
View on AACR
clincancerres.aacrjournals.org
46 Citations
Highly Influential Citations
2
Background Citations
19
Methods Citations
2

46 Citations

Citation Type

Citation Type

Role of the Microenvironment for Radiosensitization by Patupilone
TLDR
It is shown that the major cytotoxic effect of the combined treatment modality of IR and patupilone is directed against the tumor cell compartment, and the induced antiangiogenic effect derives indirectly from the tumorcell.
The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
TLDR
Patupilone represents a promising candidate to replace vincristine as part of a combined treatment strategy with ionizing radiation, and results demonstrate the potent efficacy of pat upilone against medulloblastoma cell lines.
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
TLDR
A treatment combination of MSAs with antiangiogenic agents is potent to overcome tumor cell-linked MSA resistance and should be considered as strategy for MSA-refractory tumor entities.
Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
TLDR
Canine tumor cells show inhibition of proliferation to patupilone in vitro, and a dose of 2.76 mg/m(2) IV is well tolerated in dogs with spontaneously occurring tumors.
Radiosensitizing effect of epothilone B on human epithelial cancer cells
TLDR
The results of this study showed that epothilone B displays cytotoxic antitumor activity at low nanomolar concentrations and also enhances the radiation response in the tumor cells tested; this may be induced by a reduced DNA repair capacity triggered by epothIL one B.
Epothilones in the treatment of ovarian cancer.
TLDR
Epothilones are a new group of microtubule-stabilizing agents that have demonstrated antitumor activity in taxane-resistant models and might represent a therapeutic alternative in ovarian cancer patients frequently relapse after first-line treatment based on platinum-taxane doublets.
Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer.
  • M. Edelman
  • Biology, Chemistry
    Clinical lung cancer
  • 2009
TLDR
This review evaluates 2 novel pac litaxel formulations, albumin-bound paclitaxel and paclitAXel poliglumex, and new antimicrotubulin agents, including the epothilones, colchicine-binding antivascular agents, and vinca alkaloids, are also discussed.
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
TLDR
The current preclinical, clinical pharmacokinetic and pharmacodynamic, efficacy and toxicity data of the epothilones are discussed, with a focus on ixabepilone specific.
Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.
TLDR
DR mammary adenocarcinoma MCF-7/Adr cells refractory to paclitaxel, dEpoB reduced the established tumors, markedly suppressed tumor growth, and surpassed other commonly used chemotherapy drugs such as adriamycin, vinblastine, and etoposide in beneficial effects.
Epothilones: mechanism of action and biologic activity.
  • S. Goodin, M. Kane, E. Rubin
  • Biology, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Clinical phase I and early phase II data suggest that epothilones have a broad range of antitumor activity at doses and schedules associated with tolerable side effects and are effective in paclitaxel-resistant tumor models.
BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
  • F. Lee, R. Borzilleri, +6 authors R. Kramer
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
TLDR
Efficacy data demonstrate that BMS-247550 has the potential to surpass Taxol in both clinical efficacy and ease of use (i.e., less frequent treatment schedule and/or oral administration).
In vitro studies of Taxol as a radiation sensitizer in human tumor cells.
TLDR
The inability of paclitaxel to radiosensitize A549 cells despite the presence of a G2/M block in those cells demonstrates that a G1-M block is not a sufficient condition for paclitxel radiosensitized cells.
Anticancer therapy with novel tubulin-interacting drugs.
TLDR
A number of promising 'new generation' antimitotic drugs that target the tubulin/microtubule system and display efficacy against drug-refractory carcinomas are reviewed here in terms of their mechanism(s) of action on microtubules, effectiveness againstdrug-resistant tumour cells and clinical potential.
Taxol sensitizes human astrocytoma cells to radiation.
TLDR
The results of combined taxol-radiation exposures in the human Grade III astrocytoma cell line, G18, suggest that appropriate combinations of taxol have a more than additive interaction in human tissue culture and may have a role in clinical protocols.
Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells
TLDR
It is concluded that human SCLC SBC-3 cells are sensitized to radiation by vinorelbine and that a possible mechanisms of vinurlbine-induced radiosensitization may at least in part be associated with impairment of DNA repair following radiation-induced DNA damage.
Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells.
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.
TLDR
The results are consistent with the possibility that continuous low-dose therapy with various chemotherapeutic drugs may have a highly selective effect against cycling vascular endothelial cells, and may be relevant to the use of continuous or frequent administration of low doses of certain types of drugs as an optimal way of delivering antiangiogenic therapy.
Paclitaxel (taxol).
TLDR
Continuing clinical studies will evaluate paclitaxel as initial therapy for ovarian cancer and its utility in other malignancies and major efforts are under way to develop alternative sources to increase the availability of taxene analogs and reduce the dependence on yew species.
...
1
2
3
4
5
...